To understand the differential effect of let-7b on the wild-type vs. mutant KRAS tumor cells in response to paclitaxel and gemcitabine, we first compared the endogenous levels of let-7b and KRAS in these cell lines. This evidence concerns the gene KRAS and neoplasm.